Duloxetine for the treatment of major depressive disorder

Charles Nemeroff, Alan F. Schatzberg, David J. Goldstein, Michael J. Detke, Craig Mallinckrodt, Yili Lu, Pierre V. Tran

Research output: Contribution to journalArticle

183 Citations (Scopus)

Abstract

>55% were observed in two of the studies, while in a third study the probability of remission with duloxetine treatment was nearly three times that observed with placebo (44% versus 16%). Duloxetine also produced significant improvement in painful physical symptoms compared with placebo, in many cases after only 2 weeks of treatment. The discontinuation rate due to adverse events (14.6%) was similar to those observed with selective serotonin reuptake inhibitors. The most frequently reported adverse events were nausea, dry mouth, fatigue, and insomnia. Conclusion. Duloxetine was demonstrated to be safe and effective in the treatment of MDD. The starting dose with the best balance of efficacy and tolerability is 60 mg QD.

Original languageEnglish (US)
Pages (from-to)106-132
Number of pages27
JournalPsychopharmacology Bulletin
Volume36
Issue number4
StatePublished - Sep 1 2002
Externally publishedYes

Fingerprint

Major Depressive Disorder
Placebos
Serotonin Uptake Inhibitors
Sleep Initiation and Maintenance Disorders
Nausea
Fatigue
Mouth
Therapeutics
Duloxetine Hydrochloride

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Nemeroff, C., Schatzberg, A. F., Goldstein, D. J., Detke, M. J., Mallinckrodt, C., Lu, Y., & Tran, P. V. (2002). Duloxetine for the treatment of major depressive disorder. Psychopharmacology Bulletin, 36(4), 106-132.

Duloxetine for the treatment of major depressive disorder. / Nemeroff, Charles; Schatzberg, Alan F.; Goldstein, David J.; Detke, Michael J.; Mallinckrodt, Craig; Lu, Yili; Tran, Pierre V.

In: Psychopharmacology Bulletin, Vol. 36, No. 4, 01.09.2002, p. 106-132.

Research output: Contribution to journalArticle

Nemeroff, C, Schatzberg, AF, Goldstein, DJ, Detke, MJ, Mallinckrodt, C, Lu, Y & Tran, PV 2002, 'Duloxetine for the treatment of major depressive disorder', Psychopharmacology Bulletin, vol. 36, no. 4, pp. 106-132.
Nemeroff C, Schatzberg AF, Goldstein DJ, Detke MJ, Mallinckrodt C, Lu Y et al. Duloxetine for the treatment of major depressive disorder. Psychopharmacology Bulletin. 2002 Sep 1;36(4):106-132.
Nemeroff, Charles ; Schatzberg, Alan F. ; Goldstein, David J. ; Detke, Michael J. ; Mallinckrodt, Craig ; Lu, Yili ; Tran, Pierre V. / Duloxetine for the treatment of major depressive disorder. In: Psychopharmacology Bulletin. 2002 ; Vol. 36, No. 4. pp. 106-132.
@article{bfbea93c809745029b387f88c65e59f3,
title = "Duloxetine for the treatment of major depressive disorder",
abstract = ">55{\%} were observed in two of the studies, while in a third study the probability of remission with duloxetine treatment was nearly three times that observed with placebo (44{\%} versus 16{\%}). Duloxetine also produced significant improvement in painful physical symptoms compared with placebo, in many cases after only 2 weeks of treatment. The discontinuation rate due to adverse events (14.6{\%}) was similar to those observed with selective serotonin reuptake inhibitors. The most frequently reported adverse events were nausea, dry mouth, fatigue, and insomnia. Conclusion. Duloxetine was demonstrated to be safe and effective in the treatment of MDD. The starting dose with the best balance of efficacy and tolerability is 60 mg QD.",
author = "Charles Nemeroff and Schatzberg, {Alan F.} and Goldstein, {David J.} and Detke, {Michael J.} and Craig Mallinckrodt and Yili Lu and Tran, {Pierre V.}",
year = "2002",
month = "9",
day = "1",
language = "English (US)",
volume = "36",
pages = "106--132",
journal = "Psychopharmacology Bulletin",
issn = "0048-5764",
publisher = "MedWorks Media LLC",
number = "4",

}

TY - JOUR

T1 - Duloxetine for the treatment of major depressive disorder

AU - Nemeroff, Charles

AU - Schatzberg, Alan F.

AU - Goldstein, David J.

AU - Detke, Michael J.

AU - Mallinckrodt, Craig

AU - Lu, Yili

AU - Tran, Pierre V.

PY - 2002/9/1

Y1 - 2002/9/1

N2 - >55% were observed in two of the studies, while in a third study the probability of remission with duloxetine treatment was nearly three times that observed with placebo (44% versus 16%). Duloxetine also produced significant improvement in painful physical symptoms compared with placebo, in many cases after only 2 weeks of treatment. The discontinuation rate due to adverse events (14.6%) was similar to those observed with selective serotonin reuptake inhibitors. The most frequently reported adverse events were nausea, dry mouth, fatigue, and insomnia. Conclusion. Duloxetine was demonstrated to be safe and effective in the treatment of MDD. The starting dose with the best balance of efficacy and tolerability is 60 mg QD.

AB - >55% were observed in two of the studies, while in a third study the probability of remission with duloxetine treatment was nearly three times that observed with placebo (44% versus 16%). Duloxetine also produced significant improvement in painful physical symptoms compared with placebo, in many cases after only 2 weeks of treatment. The discontinuation rate due to adverse events (14.6%) was similar to those observed with selective serotonin reuptake inhibitors. The most frequently reported adverse events were nausea, dry mouth, fatigue, and insomnia. Conclusion. Duloxetine was demonstrated to be safe and effective in the treatment of MDD. The starting dose with the best balance of efficacy and tolerability is 60 mg QD.

UR - http://www.scopus.com/inward/record.url?scp=84965188482&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84965188482&partnerID=8YFLogxK

M3 - Article

C2 - 12858150

AN - SCOPUS:84965188482

VL - 36

SP - 106

EP - 132

JO - Psychopharmacology Bulletin

JF - Psychopharmacology Bulletin

SN - 0048-5764

IS - 4

ER -